GeneDx Losses and Conference Call

But the important points are these:

1. Frost should have found a cash buyer for GeneDx, like PGDx found in LabCorp.
2. But he's a stock addict, especially when said stocks are in the 'penny' category, or have fallen like 95+%.
3. Until Opko's position in WGS is monetized, the quarter-end to quarter-end fluctuations in the price of GeneDx are just paper losses or gains. Such that, even if WGS stays around these prices until end of Q1, Opko will report a cashless/accounting gain based on the difference between the putative ~$6.50 price (if it holds thereabouts) and the $2.75 close at the end of Q4. That would be $0.019/share.
4. Which is another way of saying, it's meaningless from both a cash and operations perspective. That is to say, no investor will buy Opko stock because it recorded a 2c or 5c or 20c paper gain on an asset which 1) hasn't been monetized; 2) is still at a loss versus the original sales consideration, and 3) can be reversed in the next quarter if WGS closes lower.

Until Opko sells its shares in GeneDx for anything close to the original deal terms, WGS and its stock price is just another shiny object distraction for the perennially and proverbially screwed Opko shareholder.

Thanks Phil! Give yourself a raise!